reteplase

(redirected from Retavase)

reteplase

 [ret´ĕ-plās]
a recombinant form of tissue plasminogen activator; used intravenously as a thrombolytic agent in treatment of myocardial infarction.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

reteplase

(rĕ-tĕ'plāz),
A fibrinolytic agent that works by stimulating production of plasmin.
See also: plasmin.
Farlex Partner Medical Dictionary © Farlex 2012

PLAT

A gene on chromosome 8p12 that encodes tissue plasminogen activator, which converts inactive plasminogen to plasmin by hydrolysing a single Arg-Val bond in plasminogen, thereby playing a key role in tissue remodelling, degradation, cell migration and other cellular events. PLAT directly facilitates neuronal migration.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

reteplase

Retavase Cardiology A recombinant mutant of alteplase–tPA used to treat acute MI. See Acute myocardial infarction, GUSTO V.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

reteplase

A drug that dissolves blood clots. A fibrinolytic drug used in the early stages of a heart attack to try to restore patency to a coronary artery branch that has been blocked by a blood clot. A brand name is Rapilysin.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Currently, there are 3 FDA-approved recombinant tissue plasminogen medications: activase (Activase), tenecteplase (TNKase or "TNK"), and reteplase (Retavase).
Under the agreement sealed last month, Cornerstone paid USD125m (EUR100m) in cash for the deal and pledged additional up to USD25m payments based on certain milestones related to the targetsa[euro](tm) Retavase product, it said.
The thrombolytic drugs tested included: alteplase (Cathflo Activase, Genentech, Inc, San Francisco, California), urokinase (Abbokinase, Abbott Laboratories, Abbott Park, Illinois), streptokinase (Streptase, Aventis, Paris, France), tenecteplase (TNKase, Genentech, Inc), and reteplase (Retavase, Boehringer Mannheim, Mannheim, Germany).
So far, a variety of thrombolytic drugs have been used: tenecteplase (TNKase), reteplase (Retavase), alteplase (Activase), and urokinase.
Alteplase (Activase), reteplase (Retavase), and tenecteplase (TNKase), produced with recombinant DNA technology are not teratogenic in experimental animals and are all rated C.
Retavase is approved for use in the management of acute myocardial infarction.
Crystaal, Biovail's Canadian sales and marketing division, continued to gain market share through an expanded portfolio of products which, along with Tiazac(R), includes Retavase, Brexidol, Celexa and Cardiac STATus.
Through the acquisition, Cornerstone adds cardiovascular therapies CARDENE IV and RETAVASE to its hospital product portfolio.
All of these agents are given intravenously Alteplase (Activase), reteplase (Retavase), and tenecteplase (TNKase), produced with recombinant DNA technology are not teratogenic in animals and are all rated C.